MAM
PTGX icon

Martingale Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Martingale Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,408
Closed -$310K – 879
2021
Q3 		$310K Buy
17,408
+9,100
+110% +$388K ﹤0.01% 746
2021
Q2 		$374K Buy
+8,308
New +$274K ﹤0.01% 673
2020
Q4 		– Sell
-43,700
Closed -$855K – 1017
2020
Q3 		$855K Sell
43,700
-53,500
-55% -$1M 0.01% 676
2020
Q2 		$1.72M Buy
+97,200
New +$1.22M 0.02% 582

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Martingale Asset Management's PTGX Position: Q4 2021 in Review

Martingale Asset Management sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 17,408 shares — an estimated $310K sold.

Martingale Asset Management first reported a position in PTGX in Q2 2020 and held it in 4 quarters. The position peaked at $1.72M in Q2 2020. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

  • Martingale Asset Management reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Martingale Asset Management sold 17,408 Protagonist Therapeutics shares in Q4 2021, an estimated $310K.
  • Martingale Asset Management first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 4 quarters.
  • Martingale Asset Management's Protagonist Therapeutics position peaked at $1.72M in Q2 2020.
  • 149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on Martingale Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.